Inside AGBT: Big Announcements and Bigger Implications
Register Now Panelists:
Charlie Johnson, PhD Director,Genomics and Bioinformatics ServicesTexas A&M AgriLife Research View Bio
Panelist ...
Brainstem nerve cells found to stabilize blood pressure fluctuations
Doctors usually focus on a person's average blood pressure, but research increasingly shows that how much blood pressure fluctuates from moment to moment is just as important. Excessive short-term variability is a strong and...
On Its 15th Anniversary, Foresite Capital Looks Ahead
As it celebrates its 15th anniversary this year, Foresite Capital is looking less back than ahead. After a year that saw an uptick in biopharma venture capital (VC) dollars invested, though not in the...
Stroke care varies across Medicare coverage types
A first-of-its-kind analysis has revealed significant differences in stroke outcomes and stroke care for patients on government-run traditional Medicare plans versus those on Medicare Advantage, offered by private insurers.UVA Health researchers found that patients...
Axol Bioscience acquires ophthalmology business from Newcells Biotech
Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of Newcells Biotech (Newcells), a leading...
StockWatch: Nektar’s Rezpeg Sparks a Sweet “Comeback Story”
Four years after clinical failures sparked a convulsive restructuring that cost the company nearly 700 jobs, followed by a pivot to inflammatory skin diseases, Nektar Therapeutics (NASDAQ: NKTR) found some vindication this past week when it announced...
Insilico Medicine and MSK collaborate to discover new drug targets for gastroesophageal malignancies
Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for...
Harnessing AI to optimize the development of new protein manufacturing processes
Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds. In a new study, MIT chemical engineers have harnessed artificial intelligence to optimize the development of new...
Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins
Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific partnership. The collaboration brings together eProtein Discovery's™ rapid multiplex...
Spotlight on Organoids
REGISTER NOW Panelists:
Hans Clevers, MD, PhD ProfessorStem Cell PioneerOrganoid ResearcherHubrecht Institute, the Netherlands View Bio
Panelist ...
